



FRUZAQLA™ (fruquintinib)
RapidStart Request Form

## How the RapidStart Program\* helps

If your patient experiences a delay in insurance coverage determination of at least 5 days, they may be eligible to receive a 1-month supply of medication at no cost to them.

Patients must have a completed Takeda Oncology Here2Assist™ Enrollment Form on file to apply for the RapidStart Program. Terms and Conditions apply.\*†

## How to enroll in the RapidStart Program

- **1. COMPLETE ALL INFORMATION** on page 2 in its entirety with your patient, including prescriber information, patient information, shipping information, treatment history, statement of medical necessity, prescription request, and authorization.
- **2. SIGN AND DATE** the form. Prescriber and patient (or legal representative) authorization is required in the form of an original signature following review of the prescriber authorization and the patient authorization sections.

#### IMPORTANT: Original signatures are required.

Please ensure original signatures for the prescriber and patient (or legal representative) are applied. Stamped signatures will not be accepted. Applications that do not include original signatures cannot be processed, and your patient's enrollment may be delayed.

3. FAX the completed and signed form to Takeda Oncology Here2Assist at 1-844-269-3038.

IMPORTANT: The RapidStart Request Form is only valid if received by fax.

### Please see full Prescribing Information for FRUZAQLA.

<sup>\*</sup>The RapidStart Program provides a 1-month supply of treatment of the prescribed Takeda Oncology medication at no charge for eligible patients new to therapy experiencing a delay in insurance coverage determination of at least 5 business days. There is no purchase obligation by virtue of a patient's participation in the RapidStart Program. Patients must have an on-label, valid prescription for the Takeda Oncology medication and a medical necessity for being prescribed the Takeda Oncology medication. Patients must be enrolled in the Takeda Oncology Here2Assist Program to qualify. Free product for the RapidStart Program will only be available through the RapidStart Program noncommercial specialty pharmacy. A delay in coverage determination of at least 5 days is required for patients to be eligible for the RapidStart Program. The program may not be combined with any other offer and is not available to patients whose insurers have made a final determination to deny the patient coverage for the prescribed Takeda Oncology medication. Takeda reserves the right to change or end the program at any time. Benefits provided under the program are not transferable.

 $<sup>^\</sup>dagger$ Separate program enrollment is required for the Takeda Oncology Here2Assist Program.



# FRUZAQLA™ (fruquintinib) RapidStart Request Form

Fax to 1-844-269-3038 or call 1-844-817-6468, Option 2, Monday-Friday, 8AM-8PM ET

Complete this additional FRUZAQLA™ (fruquintinib) RapidStart Request Form for insured patients who are receiving their first prescription of FRUZAQLA and are experiencing a delay in insurance coverage determination. The FRUZAQLA RapidStart Program\* may provide eligible patients with a 1-month supply of FRUZAQLA at no cost to them. Terms and Conditions apply.\*

Please see full Prescribing Information for FRUZAQLA.

	ORMATION						
Address:			_ City:	iaa Cambaati	State:	ZIP:	
rnone: State License #·	NPI·	Fax: Medicare/Medic	Primary Off aid Provider #1	ice Contact:	Reimbursement Cor	rtact.	
PATIENT INFOR		ourdard/mourt					
			Date of Birth (M	M/DD/YYYY)·		Gender: □ Ma	le 🗍 Female
<sup></sup>		OK to leave message?	Yes No	Email:			
Лobile:		OK to leave message?	☐ Yes ☐ No				
SHIPPING INFO	RMATION						
hip to patient's home	e address indicated	above? 🔲 Yes 🔲 No. Ship to add	ress below				
atient Name:		Contact Person Name:			Phone: _		
Address:		City	: :		State: _	ZIP:	
MPORTANT: Product		•					
TREATMENT HI	STORY						
STATEMENT OF	MEDICAL NE	CESSITY					
CD-10 Code:							
PRESCRIPTION  The RapidStart Program providetermination of at least 5 but medication, and a medical ne	REQUEST: To podes a 1-month supply of the siness days. There is no prescribe to the sine	ermit medication to be sent to your carment of the prescribed Takeda Oncology medurchase obligation by virtue of a patient's particity of the Takeda Oncology medication. Patients multiple oncommercial specialty pharmary A delay in commercial specialty pharmary.	our patient, the publication at no charge for pation in the RapidStart late the Enrolled in the Take	prescription info eligible patients new Program. Patients museda Oncology Here2As	to therapy experiencing a st have an on-label, valid p sist Program to qualify. Fr	delay in insurance cove rescription for the Taked ee product for the Rapid	rage la Oncology Start Program
PRESCRIPTION  The RapidStart Program provi- letermination of at least 5 by  medication, and a medical ne  vill only be available through  program may not be combine  eserves the right to change of	REQUEST: To podes a 1-month supply of the siness days. There is no processity for being prescribent the RapidStart Program red with any other offer and or end the program at any	ermit medication to be sent to you eatment of the prescribed Takeda Oncology med irchase obligation by virtue of a patient's particly d the Takeda Oncology medication. Patients mu oncommercial specialty pharmacy. A delay in co is not available to patients whose insurers have time. Benefits provided under the program are r	our patient, the patication at no charge for dication at the RapidStart at the enrolled in the Take verage determination of made a final determinat iot transferable.	eligible patients new Program. Patients mu: eda Oncology Here2As at least 5 days is requ	to therapy experiencing a st have an on-label, valid p ssist Program to qualify. Fr ired for patients to be elio	delay in insurance cove rescription for the Taked ee product for the Rapid ible for the RapidStart F	rage da Oncology Start Program drogram, The
PRESCRIPTION The RapidStart Program provice the RapidStart Program provice the RapidStart Program provice the RapidStart Program and a medical new form the serves the right to change of the RapidStart Product	REQUEST: To podes a 1-month supply of to isiness days. There is no processity for being prescribe the RapidStart Program red with any other offer and the region of the re	ermit medication to be sent to you eatment of the prescribed Takeda Oncology med irchase obligation by virtue of a patient's particly d the Takeda Oncology medication. Patients mu oncommercial specialty pharmacy. A delay in co is not available to patients whose insurers have time. Benefits provided under the program are r	Dur patient, the patient of the patient of the patien in the RapidStart is the enrolled in the Take werage determination of made a final determinary	eligible patients new Program. Patients mu: eda Oncology Here2As at least 5 days is requ	to therapy experiencing a st have an on-label, valid p ssist Program to qualify. Fr ired for patients to be elio	delay in insurance cove rescription for the Taked ee product for the Rapid ible for the RapidStart F	rage da Oncology Start Program drogram, The
PRESCRIPTION  The RapidStart Program provi- letermination of at least 5 by  medication, and a medical ne  vill only be available through  program may not be combine  eserves the right to change of	REQUEST: To podes a 1-month supply of the siness days. There is no processity for being prescribent the RapidStart Program red with any other offer and or end the program at any DOSAGE	ermit medication to be sent to you eatment of the prescribed Takeda Oncology med irchase obligation by virtue of a patient's particly d the Takeda Oncology medication. Patients mu oncommercial specialty pharmacy. A delay in co is not available to patients whose insurers have time. Benefits provided under the program are r	our patient, the patient, the patient, the patient in the RapidStart is to enrolled in the Take verage determination of made a final determination transferable.	eligible patients new Program. Patients mu: eda Oncology Here2As at least 5 days is requ	to therapy experiencing a st have an on-label, valid p ssist Program to qualify. Fr ired for patients to be elio	delay in insurance cove rescription for the Taked ee product for the Rapid ible for the RapidStart F	rage da Oncology Start Program drogram, The
PRESCRIPTION  The RapidStart Program provide termination of at least 5 bunedication, and a medical nevill only be available through program may not be combine eserves the right to change of the product PRODUCT  FRUZAQLATM (fruquintinib)	REQUEST: To p  des a 1-month supply of t  usiness days. There is no p  ucessity for being prescribe  the RapidStart Program r  d with any other offer and  or end the program at any  DOSAGE  mg	earmit medication to be sent to your eatment of the prescribed Takeda Oncology medichase obligation by virtue of a patient's particify the Takeda Oncology medication. Patients muoncommercial specialty pharmacy. A delay in cois not available to patients whose insurers have time. Benefits provided under the program are rought.	our patient, the patient, the patient, the patient in the RapidStart is to enrolled in the Take verage determination of made a final determination transferable.	eligible patients new Program. Patients mu: eda Oncology Here2As at least 5 days is requ	to therapy experiencing a st have an on-label, valid p ssist Program to qualify. Fr ired for patients to be eliq	delay in insurance cove rescription for the Taked ee product for the Rapid ible for the RapidStart F	rage da Oncology Start Program drogram, The
PRESCRIPTION  the RapidStart Program providetermination of at least 5 by medication, and a medical newill only be available through rogram may not be combine eserves the right to change of the property of t	des a 1-month supply of t siness days. There is no poccessity for being prescribe the RapidStart Program red with any other offer and or end the program at any DOSAGEmg	rearmit medication to be sent to your eatment of the prescribed Takeda Oncology medication by virtue of a patient's particify the Takeda Oncology medication. Patients mu oncommercial specialty pharmacy. A delay in cois not available to patients whose insurers have time. Benefits provided under the program are round to the program of the DIRECTIONS	our patient, the patient, the patient, the patient in the RapidStart is be enrolled in the Take verage determination of made a final determination transferable.	prescription inf eligible patients new Program. Patients mu- da Oncology Here2A: at least 5 days is requ tion to deny the patie	to therapy experiencing a st have an on-label, valid p ssist Program to qualify. Fr ired for patients to be elig nt coverage for the prescri	delay in insurance cove rescription for the Taker ee product for the Rapid ible for the RapidStart P oed Takeda Oncology m	rage la Oncology Start Program rogram. The edication. Takeda
PRESCRIPTION  The RapidStart Program providetermination of at least 5 by medication, and a medical newill only be available through program may not be combine eserves the right to change of the property of	REQUEST: To podes a 1-month supply of the siness days. There is no processity for being prescribent the RapidStart Program red with any other offer and or end the program at any DOSAGE	earmit medication to be sent to your eatment of the prescribed Takeda Oncology medichase obligation by virtue of a patient's particify the Takeda Oncology medication. Patients muoncommercial specialty pharmacy. A delay in cois not available to patients whose insurers have time. Benefits provided under the program are rought.	pour patient, the patient, the patient, the patient in the RapidStart is to enrolled in the Take verage determination of made a final determination transferable.  **DISPENSE**  **Lady supply**  **Innosis, the patient is patient in the patient in	prescription infeligible patients new Program. Patients murda Oncology Here2A: at least 5 days is requition to deny the patients of the patien	to therapy experiencing a st have an on-label, valid p sist Program to qualify. Fr ired for patients to be elig nt coverage for the prescri	delay in insurance cove rescription for the Taker ee product for the Rapid ible for the RapidStart F oed Takeda Oncology m	rage la Oncology Start Program rogram. The edication. Takeda
PRESCRIPTION  The RapidStart Program providetermination of at least 5 by medication, and a medical newill only be available through program may not be combine eserves the right to change of the property of	des a 1-month supply of t usiness days. There is no processity for being prescribe the RapidStart Program red with any other offer and or end the program at any DOSAGE	earmit medication to be sent to your eatment of the prescribed Takeda Oncology medication. Patient's particify the Takeda Oncology medication. Patients mu oncommercial specialty pharmacy. A delay in cois not available to patients whose insurers have imme. Benefits provided under the program are round to the Takeda Oncology.  HORIZATIONS  being prescribed for an on-label diagard and understand the RapidStart Program from any goon the RapidStart Program from any goon to the RapidStart Program from the RapidStart Pr	pour patient, the particular patient, the particular patient, the particular patient in the RapidStart st be enrolled in the Take verage determination of made a final determination transferable.  **DISPENSE**  **Lady supply**  **Groosis**, the patient in gram Terms and Covernment program**	eligible patients new Program. Patients museda Oncology Here2As at least 5 days is requition to deny the patients of the patie	to therapy experiencing a st have an on-label, valid p sists Program to qualify. Fr ired for patients to be elig at coverage for the prescril st coverage for the prescril st coverage for the prescril the prescril of the prescril st coverage for the prescril of the prescribe of the prescribe of the prescrip of	delay in insurance cove rescription for the Taker se product for the Rapid ible for the RapidStart P sed Takeda Oncology m e prescription com seek reimburseme that I will not atte	rage da Oncology Start Program rogram. The edication. Takeda aplies with nt for any mpt to sell,
PRESCRIPTION  The RapidStart Program providetermination of at least 5 bunedication, and a medical newill only be available through program may not be combine eserves the right to change of the program of the property of the provided of th	des a 1-month supply of t usiness days. There is no p usessity for being prescribe the RapidStart Program r ad with any other offer and or end the program at any  DOSAGE  Mg  PATIENT AUT tify that FRUZAQLA is state laws. I have re to the patient throug dit any FRUZAQLA pr	estment of the prescribed Takeda Oncology medication to be sent to your eatment of the prescribed Takeda Oncology medication. Patients must oncommercial specialty pharmacy. A delay in coins not available to patients whose insurers have time. Benefits provided under the program are reported by the prescribed of the prescribed for an on-label diagard and understand the RapidStart Program and Understand the Rapi	pour patient, the patient of pati	eligible patients new Program. Patients murda Oncology Here2A: at least 5 days is requition to deny the patients of the patien	to therapy experiencing a st have an on-label, valid possist Program to qualify. Frired for patients to be elignt coverage for the prescrible to the prescrible treatment, and the gree that I shall not sourcer. I further certify prescribe or purchas	delay in insurance cove rescription for the Taker se product for the Rapid ible for the Rapid start Paed Takeda Oncology more prescription compared to the prescription compared to the total will not atted se FRUZAQLA or ar	rage da Oncology Start Program rogram. The edication. Takeda  applies with nt for any mpt to sell, ny other
he RapidStart Program proviletermination of at least 5 binedication, and a medical newill only be available through program may not be combinings or the combining of the combining of the complete of the combining of the combini	des a 1-month supply of to siness days. There is no processity for being prescribe the RapidStart Program red with any other offer and or end the program at any DOSAGE	reatment of the prescribed Takeda Oncology med urchase obligation by virtue of a patient's particil of the Takeda Oncology medication. Patients mu oncommercial specialty pharmacy. A delay in co is not available to patients whose insurers have time. Benefits provided under the program are rounder. Benefits provided under the RapidStart Program from any go ovided under this program. I understatify I have received nothing of value from the program and the program of the program are rounder.	pour patient, the patient, the patient, the patient in the RapidStart is the enrolled in the Take verage determination of made a final determination transferable.  CISPENSE  -day supply  gnosis, the patient in gram Terms and Covernment program and that I am unde om Takeda or its ag	eligible patients new Program. Patients museda Oncology Here2As at least 5 days is requition to deny the patients on the patients of the patie	to therapy experiencing a st have an on-label, valid possist Program to qualify. Frired for patients to be elignt coverage for the prescribent coverage for the prescribent and the gree that I shall not some actives for prescribing at ives for prescribing at ives for prescribing the street of the prescribent and the prescribent and the sure. I further certify prescribe or purchalatives for prescribing at ives for prescribing the street and the street of the street and	delay in insurance cove rescription for the Taker se product for the Rapid ible for the Rapid start Paed Takeda Oncology more prescription compared to the prescription compared to the total will not atted se FRUZAQLA or ar	rage da Oncology Start Program rogram. The edication. Takeda  applies with nt for any mpt to sell, ny other
he RapidStart Program proviletermination of at least 5 binedication, and a medical newill only be available through program may not be combinings or the combining of the combining of the complete of the combining of the combini	des a 1-month supply of to siness days. There is no processity for being prescribe the RapidStart Program red with any other offer and or end the program at any DOSAGE	eatment of the prescribed Takeda Oncology met increase obligation by virtue of a patient's particif of the Takeda Oncology medication. Patients mu oncommercial specialty pharmacy. A delay in co is not available to patients whose insurers have ime. Benefits provided under the program are round prescribed for an on-label diagard and understand the RapidStart Program from any govided under this program. I understand thus when the program are round prescribed for an on-label diagard and understand the RapidStart Program from any govided under this program. I understand the round prescribed under this program.	pour patient, the patient, the patient, the patient in the RapidStart is the enrolled in the Take verage determination of made a final determination transferable.  CISPENSE  -day supply  gnosis, the patient in gram Terms and Covernment program and that I am unde om Takeda or its ag	eligible patients new Program. Patients museda Oncology Here2As at least 5 days is requition to deny the patients on the patients of the patie	to therapy experiencing a st have an on-label, valid possist Program to qualify. Frired for patients to be elignt coverage for the prescribent coverage for the prescribent and the gree that I shall not some actives for prescribing at ives for prescribing at ives for prescribing the street of the prescribent and the prescribent and the sure. I further certify prescribe or purchalatives for prescribing at ives for prescribing the street and the street of the street and	delay in insurance cove rescription for the Taker se product for the Rapid ible for the Rapid start Paed Takeda Oncology more prescription compared to the prescription compared to the total will not atted se FRUZAQLA or ar	rage la Oncology Start Program rogram. The edication. Takeda  applies with nt for any mpt to sell, ny other
PRESCRIPTION  The RapidStart Program providetermination of at least 5 by medication, and a medical newill only be available through orogram may not be combineserves the right to change of the property of th	des a 1-month supply of to siness days. There is no processity for being prescribe the RapidStart Program red with any other offer and or end the program at any DOSAGE mg  DOSAGE mg  DOSAGE  DOSAGE  Total tify that FRUZAQLA is state laws. I have resorted the patient through the patient through the patient through the patient sine by Takeda, and I certain the patient certain the patie	reatment of the prescribed Takeda Oncology med urchase obligation by virtue of a patient's particil of the Takeda Oncology medication. Patients mu oncommercial specialty pharmacy. A delay in co is not available to patients whose insurers have time. Benefits provided under the program are rounder. Benefits provided under the RapidStart Program from any go ovided under this program. I understatify I have received nothing of value from the program and the program of the program are rounder.	pour patient, the patient of the pat	eligible patients new Program. Patients museda Oncology Here2As at least 5 days is requition to deny the patients on the patients on the patients of the patients or third-party in represents or represents or represents.	to therapy experiencing a st have an on-label, valid p sist Program to qualify. Fr ired for patients to be elig nt coverage for the prescri LA treatment, and the gree that I shall not is prescribe or purcha atives for prescribing	delay in insurance cove rescription for the Taker se product for the Rapid ible for the Rapid ible for the Rapid Start Foed Takeda Oncology more prescription composeek reimbursement that I will not atted se FRUZAQLA or arg a Takeda product	rage da Oncology Start Program rogram. The edication. Takeda  applies with nt for any mpt to sell, ny other
PRESCRIPTION  The RapidStart Program providetermination of at least 5 by medication, and a medical newill only be available through forogram may not be combineserves the right to change of the product	des a 1-month supply of to siness days. There is no processity for being prescribe the RapidStart Program red with any other offer and or end the program at any processity for being prescribers in the RapidStart Program red with any other offer and or end the program at any processity for the program at any program at a	reatment of the prescribed Takeda Oncology mee urchase obligation by virtue of a patient's particit d the Takeda Oncology medication. Patients mu oncommercial specialty pharmacy. A delay in co is not available to patients whose insurers have time. Benefits provided under the program are n  DIRECTIONS  Being prescribed for an on-label diag ad and understand the RapidStart Pro in the RapidStart Program from any go ovided under this program. I underst ify I have received nothing of value fro  e: (no stamp allowed)	cour patient, the particular patient, the particular patient, the particular patient in the RapidStart is the enrolled in the Take verage determination of made a final determination transferable.  Colspense  L-day supply  Ignosis, the patient in gram Terms and Convernment program and that I am under om Takeda or its agon Takeda or its agon Takeda or its agon original New York Statenot previously beer AQLA provided under patient in the provided under the patient in th	eligible patients new Program. Patients museda Oncology Here2As at least 5 days is requition to deny the patients on the patients of the prescription blank. For the program. In prescribed FRUZIER the program.	to therapy experiencing a st have an on-label, valid possist Program to qualify. Frired for patients to be elignt coverage for the prescribent coverage for the prescribent at labeling prescribe or purchal atives for prescribing or all other states, if not factor and I will not f I am enrolled in a last state at labeling and I will not f I am enrolled in a last states.	delay in insurance cove rescription for the Taker se product for the Rapid ible for the Rapid ible for the Rapid Start Foed Takeda Oncology more seek reimbursement at his product of the Product of the Rapid Ible Start Ford Takeda Oncology more seek reimbursement at his product of the Rapid Ible Start Ford Ible Start Ford Ible Start Ible St	rage la Oncology Start Program rogram. The edication. Takeda  applies with nt for any mpt to sell, ny other  st be on a state- ent or credit from a
PRESCRIPTION  The RapidStart Program providetermination of at least 5 bmedication, and a medical newill only be available through orogram may not be combineserves the right to change of the product of	des a 1-month supply of to siness days. There is no processity for being prescribe the RapidStart Program of the William of the program at any process. The program at any process of the program at any process. The program at any process of the program at any process. The program at any process of the program at any process. The process of the program at any process of the program at any process. If the process of the proce	eatment of the prescribed Takeda Oncology med rachase obligation by virtue of a patient's participation of the Takeda Oncology medication. Patients mu oncommercial specialty pharmacy. A delay in cois not available to patients whose insurers have time. Benefits provided under the program are not provided under the program are not provided under the program are not provided understand the RapidStart Program from any good and understand the RapidStart Program from any goovided under this program. I understainty I have received nothing of value from the New York State must submit the prescription on a construction of the program, I certify that I have regram; and will not sell or trade FRUZ.	pour patient, the patient of transferable.  DISPENSE day supply  gnosis, the patient of the p	eligible patients new Program. Patients museda Oncology Here2As at least 5 days is requition to deny the patient on the patient of the prescription blank. Find prescribed FRUZIER the program. In of my true out-of my true out-of	to therapy experiencing a st have an on-label, valid possess frogram to qualify. Frired for patients to be elignt coverage for the prescribent coverage for	delay in insurance cove rescription for the Taker se product for the Rapid ible for the R	rage la Oncology Start Program rogram. The edication. Takeda  applies with nt for any mpt to sell, ny other  st be on a state- ent or credit from a
PRESCRIPTION The RapidStart Program providetermination of at least 5 binedication, and a medical newill only be available through orogram may not be combine eserves the right to change of the program of the combine eserves the right to change of the program of the property of the prope	des a 1-month supply of to siness days. There is no processity for being prescribe the RapidStart Program of the William of the program at any process. The program at any process of the program at any process. The program at any process of the program at any process. The program at any process of the program at any process. The process of the program at any process of the program at any process. If the process of the proce	reatment of the prescribed Takeda Oncology medication to the prescribed Takeda Oncology medication. Patients mu oncommercial specialty pharmacy. A delay in co is not available to patients whose insurers have time. Benefits provided under the program are not prescribed for an on-label diagram and understand the RapidStart Program from any goovided under this program. I understify I have received nothing of value from the National State of the program are not program and the special program and the special program. I understify I have received nothing of value from the special program and the prescription on a special program, I certify that I have a special program; and will not sell or trade FRUZ item or any cost associated with it counters.	pour patient, the patient of transferable.  DISPENSE day supply  gnosis, the patient of the p	eligible patients new Program. Patients museda Oncology Here2As at least 5 days is requition to deny the patient on the patient of the prescription blank. Find prescribed FRUZIER the program. In of my true out-of my true out-of	to therapy experiencing a st have an on-label, valid possess frogram to qualify. Frired for patients to be elignt coverage for the prescribent coverage for	delay in insurance cove rescription for the Taker se product for the Rapid ible for the R	rage da Oncology Start Program rogram. The edication. Takeda  applies with nt for any mpt to sell, ny other  st be on a state- ent or credit from an, I certify drugs calculations